Astrazeneca (AZN) Income from Continuing Operations (2009 - 2026)

Astrazeneca (AZN) has reported Income from Continuing Operations for 18 consecutive years, with 833000000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 233.92% year-over-year to 833000000.0; the TTM figure through Mar 2026 stood at 922000000.0 (up 212.44% YoY), while the FY2025 annual figure was 10233000000.0, up 45.33% from the prior year.
• Income from Continuing Operations came in at 833000000.0 for Q1 2026 at Astrazeneca, up from 150000000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 1466000000.0 in Q2 2022, with the low at 935000000.0 in Q4 2022.
• Average Income from Continuing Operations over 5 years is 24705882.35, with a median of 148000000.0 recorded in 2022.
• Across the five-year window, Income from Continuing Operations plunged 3500.0% in 2022 and surged 675.0% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 935000000.0 in 2022, then advanced by 5.56% to 883000000.0 in 2023, then surged by 118.8% to 166000000.0 in 2024, then plunged by 190.36% to 150000000.0 in 2025, then jumped by 655.33% to 833000000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 833000000.0, 150000000.0, and 669000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.